William Blair Forecasts Weaker Earnings for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO) – Stock analysts at William Blair lowered their Q1 2025 earnings per share estimates for shares of Cooper Companies in a research note issued to investors on Monday, December 9th. William Blair analyst M. Andrew now forecasts that the medical device company will post earnings of $0.92 per share for the quarter, down from their prior forecast of $0.95. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. William Blair also issued estimates for Cooper Companies’ Q2 2025 earnings at $0.94 EPS, Q3 2025 earnings at $1.04 EPS and FY2025 earnings at $3.98 EPS.

COO has been the subject of a number of other research reports. Citigroup reduced their price objective on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Robert W. Baird raised their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Morgan Stanley dropped their price target on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company raised their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Finally, Piper Sandler upped their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Cooper Companies Stock Performance

Shares of COO stock opened at $96.72 on Thursday. The company’s fifty day moving average price is $103.71 and its 200-day moving average price is $98.87. The stock has a market cap of $19.26 billion, a PE ratio of 49.60, a price-to-earnings-growth ratio of 2.17 and a beta of 0.97. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. Cooper Companies has a 12 month low of $84.76 and a 12 month high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the business posted $0.87 earnings per share. Cooper Companies’s quarterly revenue was up 9.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in COO. Envestnet Portfolio Solutions Inc. boosted its position in shares of Cooper Companies by 43.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 35,233 shares of the medical device company’s stock valued at $3,076,000 after acquiring an additional 10,616 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Cooper Companies by 30.9% during the second quarter. Assenagon Asset Management S.A. now owns 535,909 shares of the medical device company’s stock valued at $46,785,000 after purchasing an additional 126,371 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after buying an additional 737,726 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Cooper Companies by 3.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 758,332 shares of the medical device company’s stock worth $66,202,000 after buying an additional 26,787 shares during the last quarter. Finally, TD Asset Management Inc purchased a new stake in shares of Cooper Companies during the 2nd quarter valued at about $53,045,000. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the sale, the chief executive officer now owns 165,273 shares in the company, valued at approximately $18,267,624.69. This trade represents a 41.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.